29.92MMarket Cap
LossP/E TTM
Briacell Therapeutics Corp
Key Figures
3.620Open
3.623High
61.67KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
0.85%Turnover Ratio
3.630Prev. Close
3.400Low
155.26KTurnover
LossP/E Static
1.04P/B
0.00%Div Yield TTM
-139.50%ROA
49.00052wk High
1.10Volume Ratio
-26.31MNet Profit
7.25MShares
-14.4132EPS TTM
1.65Beta
-171.72%ROE
4.13052wk Low
6.13%Amplitude
--Gross Margin
29.92MMarket Cap
2.11Reward/Risk
5.38%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Briacell Therapeutics Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 208 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 40.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Briacell Therapeutics Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Briacell Therapeutics Corp Highlights
StrengthsRisks
Briacell Therapeutics Corp News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Briacell Therapeutics Corp
BCTX
1
Ionis Pharmaceuticals Inc
IONS
25
Kymera Therapeutics Inc
KYMR
23
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Briacell Therapeutics Corp Info
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Ticker SymbolBCTX
CompanyBriacell Therapeutics Corp
CEOWilliams (William V)
Websitehttps://briacell.com/
Shareholders
FAQs
What is the current price of Briacell Therapeutics Corp (BCTX)?
The current price of Briacell Therapeutics Corp (BCTX) is 3.44.
What is the symbol of Briacell Therapeutics Corp?
The ticker symbol of Briacell Therapeutics Corp is BCTX.
What is the 52-week high of Briacell Therapeutics Corp?
The 52-week high of Briacell Therapeutics Corp is 49.00.
What is the 52-week low of Briacell Therapeutics Corp?
The 52-week low of Briacell Therapeutics Corp is 4.13.
What is the market capitalization of Briacell Therapeutics Corp?
The market capitalization of Briacell Therapeutics Corp is 24.94M.
Is Briacell Therapeutics Corp (BCTX) currently rated as Buy, Hold, or Sell?
According to analysts, Briacell Therapeutics Corp (BCTX) has an overall rating of Buy, with a price target of 40.00.
What is the Earnings Per Share (EPS TTM) of Briacell Therapeutics Corp (BCTX)?
The Earnings Per Share (EPS TTM) of Briacell Therapeutics Corp (BCTX) is -62.19.
